Identifying biomarkers for lung cancer immunotherapy
Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy
This study is trying to find specific markers in lung cancer patients' samples to see if they can predict how well immunotherapy treatments will work for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Samsung Medical Center Academic / other |
| Drugs / interventions | immunotherapy, chemotherapy, radiation |
| Locations | 3 sites (Seoul, Gangnam-gu and 2 other locations) |
| Trial ID | NCT03578185 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify predictive biomarkers for immunotherapy in lung cancer patients by analyzing samples such as tumor tissue, blood, and fecal material from individuals treated with immune checkpoint inhibitors. The study will collect clinical data, including demographics, treatment history, and histologic information, to correlate with the biomarker findings. Informed consent is waived for samples donated from other clinical trials, allowing for a broader analysis of existing data.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with histologically confirmed lung cancer who have been treated with immune checkpoint inhibitors.
Not a fit: Patients who have not been treated with immune checkpoint inhibitors or those under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective immunotherapy treatments for lung cancer patients.
How similar studies have performed: Other studies have shown promise in identifying biomarkers for immunotherapy, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. aged above or equal to 18 2. Histologically confirmed lung cancer patients 3. Patient treated with immune checkpoint inhibitor Exculsion Criteria: NA
Where this trial is running
Seoul, Gangnam-gu and 2 other locations
- Samsung Medical Center — Seoul, Gangnam-gu, South Korea (Recruiting)
- Seoul National University Hospital — Seoul, Joungro-gu, South Korea (Recruiting)
- Asan Medical Center — Seoul, Songpa-gu, South Korea (Not_yet_recruiting)
Study contacts
- Study coordinator: Se-hoon Lee, MD
- Email: sehoon.lee@samsung.com
- Phone: +82-10-4759-7640
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.